Recce Pharmaceuticals (ASX:RCE) said phase two clinical trials of its topical gel Recce 327 (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) showed that the gel is safe and well-tolerated with no serious adverse effects on patients, according to a Monday filing with the Australian bourse.
After 14 days of treatment, 27 out of 29 patients treated with R327G achieved the primary efficacy endpoint, the filing said.
The study's assessments observed wound healing, with the potential for full recovery after 14 days, the filing added.
Based on the trial's results, experts believe the company's registrational phase 3 study for diabetic foot infections can achieve a statistically "significant" positive endpoint after enrolling around 100 patients, the filing added.
Shares of the company rose past 2% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。